Axe Compute Inc. (AGPU)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 2 | 2 | 2 | 0 | - | - |
| Operating profit | $m | -28 | - | ||||||
| Net profit | $m | -26 | -20 | -26 | -14 | -12 | -233 | - | - |
| EPS reported | $ | -13.37 | - | ||||||
| Operating cashflow per share | $ | -0.57 | - | ||||||
| Capex per share | $ | 1.87 | - | ||||||
| FCF per share | $ | -2.44 | - | ||||||
| Free cash flow | $m | -42 | - | ||||||
| Net debt | $m | -11 | - | ||||||
| Book value equity | $m | 48 | - | ||||||
| Book value per share | $ | 2.74 | - | ||||||
| Number of shares | m | 17.43 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.61 | - | ||||||
| P/S LTM | x | 994.73 | - | ||||||
| P/FCF LTM | x | -2.93 | - | ||||||
| EV/EBITDA LTM | x | -0.50 | - | ||||||
| EV/Sales LTM | x | 921.90 | - | ||||||
| Earnings Yield LTM | % | -1.87% | - | ||||||
| FCF Yield | % | -34.10% | - | ||||||
| Quality | |||||||||
| ROE | % | -488.50% | - | ||||||
| ROIC | % | -57.56% | - | ||||||
| Operating margin | % | -226.89% | - | ||||||
| Gross margin | % | +42.03% | - | ||||||
| FCF/Sales | % | -33917.23% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -92.28% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -25.50 | - | ||||||
| Net Debt/EBITDA | x | 0.04 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | +0.09% | - | ||||||
| Net debt/Equity | x | -0.22 | - | ||||||
| Gross debt/equity | x | 0.03 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free